Granules Eyes Oncology After Exiting Ventures

Plans To Sit On Cash from Omnichem And Biocause Exits

Granules India has ambitions to become a vertically integrated player in cancer therapies after the company ended joint ventures for contract research and manufacturing services as well as for making bulk ibuprofen.

Cancer_Treatment
Granules India intnds to become a vertically integrated oncology drugs supplier • Source: Shutterstock

Raw-materials supplier Granules India has ambitions to become a vertically-integrated oncology player as it exits joint ventures in the ibuprofen manufacturing and contract research and manufacturing services arenas.

Describing the group’s push into cancer treatments as “a long-haul process,” chairman and managing director Krishna Prasad Chigurupati said the firm had begun filing drug master files for oncology active pharmaceutical ingredients

More from Generics

More from Products